Celldex Announces Upcoming Presentation Of Barzolvolimab Phase 2 Results In Chronic Spontaneous Urticaria At AAAAI 2024
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its Phase 2 clinical trial results of barzolvolimab for chronic spontaneous urticaria (CSU) will be presented at the AAAAI 2024. The study, involving 208 patients, evaluates the efficacy and safety of barzolvolimab in CSU patients unresponsive to antihistamines. Results show significant decrease in disease activity and good tolerance. The presentation is scheduled for February 24, 2024, with a webcast on February 25.
February 05, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics' announcement of presenting Phase 2 trial results of barzolvolimab for CSU at AAAAI 2024 could positively impact investor sentiment.
The announcement of presenting significant and positive Phase 2 trial results at a prestigious medical conference can be seen as a strong endorsement of the drug's potential. This could lead to increased investor confidence in Celldex Therapeutics, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100